RADIOIMAGING MOIETIES COUPLED TO PEPTIDEASE-BINDING MOIETIES FOR IMAGING TISSUES AND ORGANS THAT EXPRESS PEPTIDASES
Conjugates, methods and kits are described for imaging tissues and organs that express one or more peptidases. In a preferred embodiment of the invention, a series of di-(2-pyridylmethyl)amine (D) ligands, which can bind M(CO) 3 + [M=Tc or Re], were coupled to lisinopril (L). Aliphatic tethers with varying number of methylene groups (3, 4, 5, and 7; D(C 4 )L, D(C 5 )L, D(C 6 )L, and D(C 8 )L, respectively) were utilized, with in vitro inhibitory activity increasing with increasing number of methylene groups. The D(C 8 )L conjugate was observed to be significantly more potent than D(C 4 )L. In vivo specificity for ACE was studied in both tissue distribution and gamma imaging studies, demonstrating localization in tissues with high ACE content. Localization was blocked by pretreatment with lisinopril.
1 . A compound comprising a peptidase-binding moiety conjugated to a radiopharmaceutical moiety or an optical imaging moiety.
2 . The compound of claim 1 in which the radiopharmaceutical moiety is a radio-imaging moiety, a radio-therapeutic moiety or both.
3 . The compound of claim 1 in which the peptidase-binding moiety is selected from exopeptidase or endopeptidases inhibitors.
4 . The compound of claim 1 in which the peptidase-binding moiety comprises a carboxypeptidase-binding moiety, which, in turn, is selected from the group consisting of an inhibitor of carboxypeptidase A1, carboxypeptidase A2, carboxypeptidase B, mast cell carboxypeptidase A, carboxypeptidase D, carboxypeptidase E, carboxypeptidase M, carboxypeptidase N, or carboxypeptidase Z.
5 . The compound of claim 4 in which the carboxypeptidase-binding moiety comprises an ACE-binding moiety.
6 . The compound of claim 5 in which the ACE-binding moiety is selected from the group consisting of alacepril, benazepril, captopril, ceronapril, cilazapril, delapril, enalapril, enalaprilat, fosinopril, imidapril, lisinopril, moexipril, moveltipril, pentopril, perindopril, quinapril, ramipril, rentiapril, spirapril, temocapril, trandolapril, or zofenopril.
7 . The compound of claim 1 in which the radio-imaging moiety comprises a radionuclide chelate complex.
8 . The compound of claim 7 in which the radionuclide is selected from technetium or rhenium.
9 . The compound of claim 8 in which the radionuclide is selected from technetium-99m, rhenium-186, or rhenium-188.
10 . The compound of claim 1 in which the radio-imaging moiety comprises a (technetium-99m)Tc(CO) 3 or (rhenium-186/188)Re(CO) 3 chelate complex.
11 . The compound of claim 5 in which the ACE-binding moiety inhibits tissue ACE to a greater extent than serum ACE.
12 . The compound of claim 5 whose IC 50 inhibition of ACE is less than 20 nM.
13 . The compound of claim 1 in which the peptidase-binding moiety and the radio-imaging moiety are conjugated via an amide, ester, amine, or ether linkage.
14 . A method of imaging one or more organs or tissues or both of a mammal comprising administering to a mammal an effective amount of a compound comprising a peptidase-binding moiety conjugated to a radio-imaging moiety or an optical imaging moiety and obtaining an image of one or more organs or tissues or both of the mammal.
15 . The method of claim 14 in which the compound is administered intravenously.
16 . The method of claim 14 in which the compound is selected from the group consisting of cold rhenium-labeled or technetium-99m-labeled D(C4)L (1), D(C5)L (2), D(C6)L (3), or D(C8)L (4).
17 . The method of claim 14 in which the one or more organs or tissues or both includes lung tissue.
18 . The method of claim 14 in which the one or more organs or tissues or both includes kidney tissue.
19 . The method of claim 14 in which the one or more organs or tissues or both includes heart tissue.
20 . The method of claim 14 in which the one or more organs or tissues or both includes tumor tissue.
21 . The method of claim 14 in which the one or more organs or tissues or both includes a vulnerable plaque condition.
22 . The method of claim 14 in which the one or more organs or tissues or both includes an atherosclerotic condition.
23 . The method of claim 14 in which the one or more organs or tissues or both includes an inflammatory condition.
24 . A kit comprising: (i) compound comprising a peptidase-binding moiety conjugated to a metal chelating moiety, and (ii) radionuclide.
25 . The kit of claim 24 in which the radionuclide is selected from technetium-99m, rhenium-186, rhenium-188 or combinations thereof.
26 . A method of staging a pathological condition associated with one or more organs or tissues or both of a mammal comprising: (i) administering to a mammal an effective amount of a compound comprising a peptidase-binding moiety conjugated to a radio-imaging moiety, (ii) obtaining an image of the one or more organs or tissues or both of said mammal; (iii) determining from said image the amount of peptidase which is present in the one or more organs or tissues or both of said mammal, and (iv) utilizing the amount determined and a control amount to arrive at a stage of the pathological condition.
27 . The method of claim 26 in which the pathological condition is selected from the group consisting of heart failure, cardiomyopathy, lung disease, kidney dysfunction, renal failure, inflammation, atherosclerosis, vulnerable arterial plaques or neoplasm.
28 . A method of monitoring a mammal's response to therapy for a pathological condition associated with one or more organs or tissues or both of the mammal comprising (i) administering to a mammal an effective amount of a compound comprising a peptidase-binding moiety conjugated to a radio-imaging moiety, (ii) obtaining an image of the one or more organs or tissues or both of the mammal, (iii) determining from said image the amount of peptidase which is present in the one or more organs or tissues or both of the mammal, and (iv) utilizing the amount determined and a control amount to gauge the mammal's response, if any, to a therapy.
29 . The method of claim 26 in which the control amount is obtained from an amount found in a group of normals.
30 . The method of claim 26 in which the control amount is obtained from a baseline amount found in the one or more organs of said mammal.
31 . The method of claim 28 in which the control amount is obtained from an amount found in a group of normals.
32 . The method of claim 28 in which the control amount is obtained from a baseline amount found in the one or more organs of the mammal.
33 . A method of quantifying expression of a peptidase in one or more organs or tissues or both of a mammal comprising administering to a mammal an effective amount of a compound including a peptidase-binding moiety conjugated to a radio-imaging moiety, obtaining an image of the one or more organs or tissues or both of the mammal; quantifying from the image and a series of standard images an amount of expression of the peptidase in the one or more organs or tissues or both of the mammal.
34 . A method of subjecting a mammal in need thereof to radiotherapeutic treatment comprising administering to a mammal an effective amount of a compound comprising a peptidase-binding moiety conjugated to a radiotherapeutic moiety.
35 . The method of claim 34 in which the compound is administered intravenously.
36 . The method of claim 34 in which the mammal is suffering from a neoplastic condition.
37 . A compound of the following formula:
(PBM) n -(LIN)-(CHE) m
wherein
PBM comprises a peptidase binding moiety,
n is 1, 2 or 3,
LIN is a covalent bond, —CH 2 —, —NH—, or a linear or branched chain that is 2-20 carbon atoms in length, and optionally bonded to or within the chain are 1-6 heteroatoms including amino, oxygen, sulfur, carbonyl, urea, or amide, aromatic rings, cyclic aliphatic rings, heteroaromatic rings, or heterocyclic aliphatic rings, and which covalently links the one or more PBMs with the one or more CHEs;
CHE comprises a chelating moiety that can be a monodentate, bidentate or polydentate ligand capable of binding a radionuclide and
m is 1, 2 or 3.
38 . The compound of claim 37 , wherein the peptidase binding moiety is an inhibitor of carboxypeptidase A1, carboxypeptidase A2, carboxypeptidase B, mast cell carboxypeptidase A, carboxypeptidase D, carboxypeptidase E, carboxypeptidase M, carboxypeptidase N, or carboxypeptidase Z.
39 . The compound of claim 37 , wherein the peptidase binding moiety is alacepril, benazepril, captopril, ceronapril, cilazapril, delapril, enalapril, enalaprilat, fosinopril, imidapril, lisinopril, moexipril, moveltipril, pentopril, perindopril, quinapril, ramipril, rentiapril, spirapril, temocapril, trandolapril, or zofenopril.
40 . The compound of claim 37 , wherein the linker is a 2-15 atom chain, wherein in 1-6 atoms of the chain are amino, oxygen, sulfur, carbonyl, urea or amide and the rest of the atoms of the chain are carbon.
41 . The compound of claim 40 , wherein the linker comprises a lysine or a lysine analogue, such as the lysine analogues shown in FIGS. 6 or FIGS. 7 .
42 . The compound of claim 37 , wherein the radionuclide is Tc or Re.
43 . The compound of claim 37 , wherein the CHE moiety is pyridylmethylene amine, quinolinemethylene amine, isoquinoline amine, pyridine-2-ylmethylamino acetic acid, isoquinolin-3-yhnethylamino acetic acid, thiazol-2-ylmethyl amine, and thiazol-2-ylmethylamino acetic acid or chelators of the following structures, which are shown as being bound to Tc:
R 8 is selected from the group O, H, OH, alkoxy, or O-alkyl;
R 9 is a pharmaceutically acceptable heterocycle, such as a 5 or 6 membered ring with 1-2 nitrogen, oxygen or sulfur atoms,
R 8 is selected from the group O, H, OH, alkoxy, or O-alkyl;
R 9 is a pharmaceutically acceptable heterocycle, such as a 5 or 6 membered ring with 1-2 nitrogen, oxygen or sulfur atoms,
R 10 and R 11 are each independently hydrogen, alkyl, or substituted alkyl;
R 12 is selected from the group of aryl, alkyl, or heterocycle;
R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 are independently Hydrogen or methyl